Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Discover a study comparing ultrasound and CBCT for bladder monitoring in prostate cancer radiotherapy to improve accuracy and ...

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

"This is the first comparison between two prostate cancer populations focusing on chimeric RNAs," Li said. "It is also the first study to examine chimeric RNAs in different cell types within cancer." ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

However, the American Cancer Society currently recommends that men with average risk of prostate cancer get screened beginning at age 50, if they are expected to live at least 10 more years, and ...